What is the reported acquisition target and estimated value in Eli Lilly's potential deal, according to the Wall Street Journal?

According to the Wall Street Journal report cited in the news body, Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion.

Has Reuters confirmed the Wall Street Journal's report about Eli Lilly's potential acquisition of Kelonia Therapeutics?

No, Reuters could not immediately verify the Wall Street Journal's report about Eli Lilly's potential acquisition of Kelonia Therapeutics.

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

Apr 19, 2026

Eli Lilly is reportedly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, per the Wall Street Journal. Reuters noted it could not immediately verify the report.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks